StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a sell rating to a hold rating in a research note released on Monday.
Abeona Therapeutics Stock Down 5.0 %
Shares of NASDAQ ABEO opened at $7.53 on Monday. The business has a fifty day simple moving average of $7.44 and a two-hundred day simple moving average of $5.59. The firm has a market cap of $205.95 million, a PE ratio of -2.92 and a beta of 1.49. Abeona Therapeutics has a twelve month low of $2.83 and a twelve month high of $9.01.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). On average, research analysts expect that Abeona Therapeutics will post -1.83 earnings per share for the current year.
Institutional Inflows and Outflows
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
- Five stocks we like better than Abeona Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Comprehensive PepsiCo Stock Analysis
- 3 Monster Growth Stocks to Buy Now
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- The 3 Best Fintech Stocks to Buy Now
- Bear Market Funds to Watch This Year
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.